Abstract
Studies in vitro showed that sodium pentosan polysulphate (SPP) is an active inhibitor of calcium oxalate crystal growth and agglomeration and that it acts by increasing the negative zeta potential on the surface of calcium oxalate crystals. Oral administration to human subjects resulted in an increase in the negative zeta potential, which is consistent with an increase in the polyanionic inhibitory activity of urine. SPP may offer a novel approach to the medical management of recurrent calcium oxalate stone disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
